The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy

Laura Bonanno; Carlota Costa; Margarita Majem; Jose Javier Sanchez; Ana Gimenez-Capitan; Ignacio Rodriguez; Alain Vergnenegre; Bartomeu Massuti; Adolfo Favaretto; Massimo Rugge; Cinta Pallares; Miquel Taron; Rafael Rosell

The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy

Laura Bonanno, Carlota Costa, Margarita Majem, Jose Javier Sanchez, Ana Gimenez-Capitan, Ignacio Rodriguez, Alain Vergnenegre, Bartomeu Massuti, Adolfo Favaretto, Massimo Rugge, Cinta Pallares, Miquel Taron, Rafael Rosell

Istituto Oncologico Veneto

Research output: Contribution to journal › Article › peer-review

Abstract

Platinum-based chemotherapy is the standard first-line treatment for non-oncogene- addicted non-small cell lung cancers (NSCLCs) and the analysis of multiple DNA repair genes could improve current models for predicting chemosensitivity. We investigated the potential predictive role of components of the 53BP1 pathway in conjunction with BRCA1. The mRNA expression of BRCA1, MDC1, CASPASE3, UBC13, RNF8, 53BP1, PIAS4, UBC9 and MMSET was analyzed by real-time PCR in 115 advanced NSCLC patients treated with first-line platinum-based chemotherapy. Patients expressing low levels of both BRCA1 and 53BP1 obtained a median progression-free survival of 10.3 months and overall survival of 19.3 months, while among those with low BRCA1 and high 53BP1 progression-free survival was 5.9 months (P

Original language	English
Pages (from-to)	1572-1581
Number of pages	10
Journal	Oncotarget
Volume	4
Issue number	10
Publication status	Published - Oct 2013

Keywords

53BP1
BRCA1
DNA repair
Platinum
Predictive modeling

ASJC Scopus subject areas

Oncology

Fingerprint Dive into the research topics of 'The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy'. Together they form a unique fingerprint.

Cite this

Bonanno, L., Costa, C., Majem, M., Sanchez, J. J., Gimenez-Capitan, A., Rodriguez, I., Vergnenegre, A., Massuti, B., Favaretto, A., Rugge, M., Pallares, C., Taron, M., & Rosell, R. (2013). The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy. Oncotarget, 4(10), 1572-1581.

The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy. / Bonanno, Laura; Costa, Carlota; Majem, Margarita; Sanchez, Jose Javier; Gimenez-Capitan, Ana; Rodriguez, Ignacio; Vergnenegre, Alain; Massuti, Bartomeu; Favaretto, Adolfo; Rugge, Massimo; Pallares, Cinta; Taron, Miquel; Rosell, Rafael.

In: Oncotarget, Vol. 4, No. 10, 10.2013, p. 1572-1581.

Research output: Contribution to journal › Article › peer-review

Bonanno, L, Costa, C, Majem, M, Sanchez, JJ, Gimenez-Capitan, A, Rodriguez, I, Vergnenegre, A, Massuti, B, Favaretto, A, Rugge, M, Pallares, C, Taron, M & Rosell, R 2013, 'The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy', Oncotarget, vol. 4, no. 10, pp. 1572-1581.

Bonanno, Laura ; Costa, Carlota ; Majem, Margarita ; Sanchez, Jose Javier ; Gimenez-Capitan, Ana ; Rodriguez, Ignacio ; Vergnenegre, Alain ; Massuti, Bartomeu ; Favaretto, Adolfo ; Rugge, Massimo ; Pallares, Cinta ; Taron, Miquel ; Rosell, Rafael. / The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy. In: Oncotarget. 2013 ; Vol. 4, No. 10. pp. 1572-1581.

@article{738057fb11fb4b90a3dff7ec5cda4199,

title = "The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy",

abstract = "Platinum-based chemotherapy is the standard first-line treatment for non-oncogene- addicted non-small cell lung cancers (NSCLCs) and the analysis of multiple DNA repair genes could improve current models for predicting chemosensitivity. We investigated the potential predictive role of components of the 53BP1 pathway in conjunction with BRCA1. The mRNA expression of BRCA1, MDC1, CASPASE3, UBC13, RNF8, 53BP1, PIAS4, UBC9 and MMSET was analyzed by real-time PCR in 115 advanced NSCLC patients treated with first-line platinum-based chemotherapy. Patients expressing low levels of both BRCA1 and 53BP1 obtained a median progression-free survival of 10.3 months and overall survival of 19.3 months, while among those with low BRCA1 and high 53BP1 progression-free survival was 5.9 months (P ",

keywords = "53BP1, BRCA1, DNA repair, Platinum, Predictive modeling",

author = "Laura Bonanno and Carlota Costa and Margarita Majem and Sanchez, {Jose Javier} and Ana Gimenez-Capitan and Ignacio Rodriguez and Alain Vergnenegre and Bartomeu Massuti and Adolfo Favaretto and Massimo Rugge and Cinta Pallares and Miquel Taron and Rafael Rosell",

year = "2013",

month = oct,

language = "English",

volume = "4",

pages = "1572--1581",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "10",

}

TY - JOUR

T1 - The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy

AU - Bonanno, Laura

AU - Costa, Carlota

AU - Majem, Margarita

AU - Sanchez, Jose Javier

AU - Gimenez-Capitan, Ana

AU - Rodriguez, Ignacio

AU - Vergnenegre, Alain

AU - Massuti, Bartomeu

AU - Favaretto, Adolfo

AU - Rugge, Massimo

AU - Pallares, Cinta

AU - Taron, Miquel

AU - Rosell, Rafael

PY - 2013/10

Y1 - 2013/10

N2 - Platinum-based chemotherapy is the standard first-line treatment for non-oncogene- addicted non-small cell lung cancers (NSCLCs) and the analysis of multiple DNA repair genes could improve current models for predicting chemosensitivity. We investigated the potential predictive role of components of the 53BP1 pathway in conjunction with BRCA1. The mRNA expression of BRCA1, MDC1, CASPASE3, UBC13, RNF8, 53BP1, PIAS4, UBC9 and MMSET was analyzed by real-time PCR in 115 advanced NSCLC patients treated with first-line platinum-based chemotherapy. Patients expressing low levels of both BRCA1 and 53BP1 obtained a median progression-free survival of 10.3 months and overall survival of 19.3 months, while among those with low BRCA1 and high 53BP1 progression-free survival was 5.9 months (P

AB - Platinum-based chemotherapy is the standard first-line treatment for non-oncogene- addicted non-small cell lung cancers (NSCLCs) and the analysis of multiple DNA repair genes could improve current models for predicting chemosensitivity. We investigated the potential predictive role of components of the 53BP1 pathway in conjunction with BRCA1. The mRNA expression of BRCA1, MDC1, CASPASE3, UBC13, RNF8, 53BP1, PIAS4, UBC9 and MMSET was analyzed by real-time PCR in 115 advanced NSCLC patients treated with first-line platinum-based chemotherapy. Patients expressing low levels of both BRCA1 and 53BP1 obtained a median progression-free survival of 10.3 months and overall survival of 19.3 months, while among those with low BRCA1 and high 53BP1 progression-free survival was 5.9 months (P

KW - 53BP1

KW - BRCA1

KW - DNA repair

KW - Platinum

KW - Predictive modeling

UR - http://www.scopus.com/inward/record.url?scp=84886734160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886734160&partnerID=8YFLogxK

M3 - Article

C2 - 24197907

AN - SCOPUS:84886734160

VL - 4

SP - 1572

EP - 1581

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 10

ER -